SignatureFD’s Enveric Biosciences ENVB Stock Holding History

SignatureFD’s Portfolio ENVB Stock Details ENVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1	Closed	-$19.4K	–	3086
2021 Q2	$17K	Buy	+1	New	+$21.4K	﹤0.01%	1777

Other funds holding ENVB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

IWC

Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return

SignatureFD's ENVB Position: Q3 2021 in Review

SignatureFD sold out of Enveric Biosciences (ENVB) in Q3 2021, closing a stake of 1 share — an estimated $19.4K sold.

SignatureFD first reported a position in ENVB in Q2 2021 and held it in 1 quarter. The position peaked at $17K in Q2 2021. 18 funds tracked by Wall St. Rank hold ENVB as of Q3 2021.

SignatureFD reported no remaining Enveric Biosciences position as of Q3 2021 after selling out during the quarter.
SignatureFD sold 1 Enveric Biosciences share in Q3 2021, an estimated $19.4K.
SignatureFD first reported a position in Enveric Biosciences in Q2 2021 and held it in 1 quarter.
SignatureFD's Enveric Biosciences position peaked at $17K in Q2 2021.
18 funds tracked by Wall St. Rank held Enveric Biosciences as of Q3 2021.

Based on SignatureFD's 13F filing for Q3 2021, filed 28 Oct 2021.